Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Novavax Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.35 (market cap $15.33M), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 85.5× Avalanche Treasury Corporation Class A Common Stock's market cap, and Novavax Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | NVAX | |
|---|---|---|
Market Cap | $15.33M | $1.31B |
Sector | Financials | Health |
52-Week High | $10.75 | $11.19 |
52-Week Low | $0.30 | $6.22 |
Enterprise Value | $15.33M | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.37, up 9.83% in the past 24 hours. The stock shows a bearish technical signal with negative cash flow from operations of -$930,710 in 2025, though net income is positive at $8.28 million. Recent news highlights its Nasdaq listing as an operating company focused on capital allocation.
The outlook is cautious due to weak operational cash flow and bearish technical indicators. Investment appeal hinges on improved profitability and cash generation. Key risks include execution challenges and market volatility.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
